FDA guidance on cell/tissue donor screening test:
This article was originally published in Clinica
Executive Summary
The FDA has issued a guidance on how manufacturers, which currently sell test kits to screen for the presence of disease in a cadaveric blood specimen, can expand the indication so the test can be used to screen for disease in donors of human cells, tissues and cellular and tissue-based products. Such a screening test is now necessary in the wake of a recent final rule requiring that donors of cells and tissue be tested for the presence of certain communicable diseases. Currently, only one company - Genetic Systems, a subsidiary of Sanofi Diagnostics Pasteur - markets a test kit for cadaveric blood specimens.
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.